Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11851466 Targeted IL-12 heterodimeric Fc-fusion proteins

Patent 11851466 was granted and assigned to Xencor on December, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Xencor

Current Assignee

Xencor

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

118514660

Patent Inventor Names

Matthew Bernett0

John R. Desjarlais0

Rumana Rashid0

Ke Liu0

Rajat Varma0

Michael Hedvat0

Nargess Hassanzadeh-Kiabi0

Date of Patent

December 26, 2023

Patent Application Number

170624580

Date Filed

October 2, 2020

Patent Citations

‌

US Patent 10696722 Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same

‌

US Patent 7141651 Multiple cytokine protein complexes

‌

US Patent 10550185 Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments

‌

US Patent 11358999 IL-12 heterodimeric Fc-fusion proteins

Patent Primary Examiner

‌

Claire Kaufman

Patent abstract

The present invention relates to targeted IL-12 heterodimeric Fc fusion proteins, where the fusion proteins bind to human PD-1 or human PD-L1.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11851466 Targeted IL-12 heterodimeric Fc-fusion proteins

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API